| abstract |
The present invention relates to inhibitors of cancer-related CXC receptor 4 (CXCR4)-G protein-coupled receptor (GPCR) heteromers (CXCR4-GPCR heteromers), wherein CXCR4 is associated with other G protein-coupled receptors ( GPCRx) to form functional heteromers. More specifically, the present invention relates to GPCRx that form heteromers with CXCR4, which upon co-stimulation with a CXCR4 agonist and a GPCRx agonist result in enhanced signaling downstream of CXCR4. The present invention also provides inhibitors of the interacting GPCR partners of the CXCR4-GPCRx heteromers or specific inhibitors of CXCR4-GPCRx heteromers, including inhibitors of the CXCR4-GPCRx heteromer formation and CXCR4-GPCRx heteromers Use of aggregate-specific antibodies, and in the diagnosis and/or treatment of cancer. |